ClinicalTrials.gg
RecruitingNCT03592472Updated Apr 13, 2025

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

A Phase 3 interventional study of Pazopanib and Abexinostat in Renal Cell Carcinoma, sponsored by Xynomic Pharmaceuticals, Inc.. Recruiting at 38 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-13.

Sponsored by Xynomic Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2018; still recruiting 8 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
413
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,144 studies in Carcinoma, Renal Cell with a site in United States — 154 open to participants now, 278 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Planned enrollment
75th of 1,010
413 · median 40
Started
2018
with 49 others
Phase 3
73 of 1,144
8 open now
Primary completion
2026-12
later than 70 of 276 live
Registered
735th of 1,144
by date

Among the 1,144 studies in Carcinoma, Renal Cell with a site in United States, this one is the 75th largest by planned enrollment of the 1,010 interventional ones that give a count, is one of 50 that started in 2018, is one of 73 in phase 3, reaches primary completion later than 70 of the 276 other live ones, and was the 735th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

154 of the 1,144 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

149 more — sign in →

All 154 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,144 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).

Read the detailed description

In this randomized, Phase 3, double-blind, placebo-controlled study, patients will be randomized 2:1 to receive either a combination of pazopanib plus abexinostat or pazopanib plus placebo. At the time of disease progression, patient treatment assignment will be unblinded, and those patients randomized to the pazopanib plus placebo treatment arm will have the option of crossing over to receive treatment with a combination of pazopanib plus abexinostat. After providing written informed consent, patients will be screened for study eligibility within 28 days before their first dose of study drug. After screening assessments, patients who are eligible for inclusion in the study will be randomized and receive their first dose of study drug on Cycle 1 Day 1 (C1D1), within 7 days of randomization. A treatment cycle is 28 days in length. Patients may continue to receive study drug until any of the following events: the development of IRC-verified radiographic progression as assessed by RECIST version 1.1, clinical disease progression, unacceptable toxicity, another discontinuation criterion is met, withdrawal of consent, or closure of the study by the sponsor. No maximum duration of therapy has been set.

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • Renal Cell Carcinoma
  • Progression-free survival
  • Abexinostat
  • Pazopanib
  • RECIST
  • Cancer therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be enrolled in the study, patients will be required to meet all of the following criteria:

  • Patients aged ≥ 18 years at time of study entry.
  • Patients have confirmed RCC with clear cell component.
  • Patients have locally advanced and unresectable or disease.
  • as assessed only by the investigator (not verified by IRC) according to version 1.1.
  • Patients must not have had any prior vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor treatment in either (neo) or locally advanced/metastatic setting. Up to 1 line of prior cytokine or treatment is allowed in either the (neo)adjuvant or metastatic setting provided screening scans indicate progressive disease (PD) during or following completion of treatment.
  • Patients have (ECOG) performance status of 0 or 1.
  • Patients have adequate baseline organ function.
  • Patients have adequate baseline hematologic function
  • Patient must be at least 2 weeks from last systemic treatment or dose of radiation prior to date of randomization.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria at Screening will not be enrolled in the study:

  • Has persistent toxicities (Grade ≥ 2; per version 5 from previous anticancer therapy (excluding alopecia which is permitted and excluding Grades 2 and 3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the investigator, and can be managed with available medical therapies).
  • Has untreated central nervous system (CNS) . Patients with treated are eligible provided imaging demonstrates no new or progressive metastases obtained at least 4 weeks following completion of treatment. CNS imaging during Screening is not required unless clinically indicated.
  • Has an additional requiring treatment within the past 3 years. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, and non-muscle invasive urothelial carcinoma.
  • Poorly controlled hypertension, defined as systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 100 mmHg. Use of anti-hypertensives and rescreening is permitted.
  • A new pulmonary embolism or deep venous thrombosis diagnosed within 3 months prior to randomization.
  • Has a interval > 480 msec.
  • Class III or IV congestive heart failure.
  • Use of prohibited medication within 7 days or 5 half-lives, whichever is shorter, prior to first dose of study drug.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
413 participants (estimated)

Study arms

  • Experimental
    Pazopanib plus abexinostat

    Randomized patients will receive a combination of pazopanib plus abexinostat. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat p.o twice daily (BID) on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of abexinostat at the same time each day.

    Drug: Pazopanib · Drug: Abexinostat

  • Placebo comparator
    Pazopanib plus placebo

    Randomized patients will receive a combination of pazopanib plus abexinostat matching placebo. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat matching placebo p.o BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of placebo at the same time each day.

    Drug: Pazopanib · Other: Placebo

Interventions

  • All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.

    Also known as: Votrient®

  • The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.

    Also known as: PCI-24781

  • OtherPlacebo

    The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assessed by blinded Independent Review Committee (IRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: From randomization date to date of first documentation of progression OR death (up to approximately 4 years).

Secondary outcomes

  1. PFS by investigator assessment according to RECIST version 1.1.

    To compare the PFS between treatment arms by investigator assessment. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assessed by IRC according to RECIST version 1.1.

    Time frame: From randomization date to date of first documentation of progression OR death (up to approximately 4 years).

  2. Overall survival (OS)

    OS is defined as the interval between date of randomization and date of death. The main objective was to compare the OS between treatment arms by investigator assessment.

    Time frame: From progression or end of study, every 3 months follow up until death, patient withdrawal from study follow-up, or study closure, whichever occurs first (up to approximately 4 years).

  3. Adverse events by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5

    To characterize the safety profile of pazopanib in combination with abexinostat.

    Time frame: From Day 1 until end of treatment visit (up to approximately 4 years).

  4. Objective response rate (ORR)

    ORR is defined as the proportion of patients with objective evidence of CR or PR by RECIST version 1.1. The main objective was to compare the ORR between treatment arms by investigator assessment.

    Time frame: Screening, Cycle 3 Day 1 (C3D1), Cycle 5 Day 1 (C5D1), Cycle 7 Day 1 (C7D1), and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).

  5. Duration of response (DOR)

    DOR is defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause by RECIST version 1.1. The main objective was to compare the DOR between treatment arms by investigator assessment.

    Time frame: Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).

  6. ORR by RECIST version 1.1 in cross-over patient population

    To describe the ORR in patients who cross over to receive pazopanib plus abexinostat at the time of disease progression on pazopanib monotherapy by investigator assessment.

    Time frame: Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).

  7. DOR by RECIST version 1.1 in cross-over patient population

    To describe the DOR in patients who cross over to receive pazopanib plus abexinostat at the time of disease progression on pazopanib monotherapy by investigator assessment.

    Time frame: Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).

  8. Mean change from Baseline in Functional Assessment of Cancer Therapy Kidney System Index (FKSI-19) scores

    To assess the impact of pazopanib with or without abexinostat on disease-related symptoms and health-related quality of life (QoL) by investigator assessment. QoL will be assessed by measuring change from baseline in FKSI-19. The FKSI-19 assesses disease-related symptoms experienced in the past 7 days. Patients are asked to respond to 12 questions ("I have a lack of energy," "I feel pain," for example) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 48).

    Time frame: First day of treatment Cycle1, Cycle 2, Cycle 6 (each cycle is 28 days in length) until end-of-treatment visit (up to approximately 4 years).

  9. Mean change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT-F) scores

    To assess the impact of pazopanib with or without abexinostat on disease-related symptoms and QoL by investigator assessment. QoL will be assessed by measuring change from baseline in FACIT-F. The FACIT-F scale measures QoL experienced in the past seven days. The measurement consisted of 5 domains (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns) assessed on a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much).

    Time frame: First day of treatment Cycle1, Cycle 2, Cycle 6 (each cycle is 28 days in length) and at end-of-treatment visit (up to approximately 4 years).

07

Study locations

1 of 38 sites recruiting
  • University Of UA Cancer Center(UACC)/DH-SJHMC
    Phoenix, Arizona 85004, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • UCSF Helen Diller Family Comphrensive Cancer Center - Hemato
    San Francisco, California 94158, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Norton Cancer Institute, Norton Healthcare Pavilion
    Louisville, Kentucky 40202, United States
    Completed

    Not enrolling at this site — choose another above.

  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
    Completed

    Not enrolling at this site — choose another above.

  • GU Research Network/Urology Cancer Center
    Omaha, Nebraska 68130, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
    Completed

    Not enrolling at this site — choose another above.

  • Northwell Health/Monter Cancer Center
    Lake Success, New York 11042, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Mainstreet Physicans Care
    Rochester, New York 14642, United States
    Completed

    Not enrolling at this site — choose another above.

  • Precision Cancer Research/Dayton Physicians Network - Treatment
    Kettering, Ohio 45409, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Oregon Health and Science University
    Portland, Oregon 97239, United States
    Completed

    Not enrolling at this site — choose another above.

  • St. Luke's Hospital
    Easton, Pennsylvania 18045, United States
    Completed

    Not enrolling at this site — choose another above.

  • HOPE Cancer Center of East Texas
    Tyler, Texas 75701, United States
    Completed

    Not enrolling at this site — choose another above.

  • Medical Oncology Associates, PS (dba Summit Cancer Centers)
    Spokane, Washington 99208, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Beijing Cancer Hospital
    Beijing, 100142, China
    Recruiting
  • Zhongshan Hospital Affiliated to Fudan University
    Shanghai, 200032, China
    Not yet recruiting
  • Fondazione del Piemonte per l'Oncologia_Istituto di Candiolo, IRCCS_ Oncologia Medica
    Candiolo, 10060, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • A.O. Cannizzaro_UOS Oncologia Medica
    Catania, 95126, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) UO Oncologia Medica
    Meldola (FC), 47014, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Istituto Europeo di Oncologia_Unità Oncologia Medica Urogenitale e Cervico Facciale
    Milano, 20141, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Istituto Nazionale dei Tumori-Fondazione Pascale- SC Oncologia Medica
    Napoli, 80131, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero-Universitaria Maggiore della Carità Novara_SC Oncologia Medica
    Novara, 28100, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Istituti Clinici Scientifici Maugeri Spa-SB_ UO Oncologia Medica
    Pavia, 27100, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero Universitaria Pisana_ UO Oncologia Medica Universitaria
    Pisa, 56126, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Fondazione Policlinico Universitario A. Gemelli, U.O.C. Oncologia Medica
    Roma, '00168, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • National Cancer Center - Center For Prostate Cancer
    Goyang-si, 10408, Korea, Republic of
    Completed

    Not enrolling at this site — choose another above.

  • CHA Bundang Medical Center, CHA University
    Seongnam-si, 13496, Korea, Republic of
    Completed

    Not enrolling at this site — choose another above.

  • Severance Hospital, Yonsei University Health System - Medical Oncology
    Seoul, 03722, Korea, Republic of
    Completed

    Not enrolling at this site — choose another above.

  • Asan Medical Center - University of Ulsan College of Medicin
    Seoul, 05505, Korea, Republic of
    Completed

    Not enrolling at this site — choose another above.

  • Samsung Medical Center - Hematology-Oncology
    Seoul, 06351, Korea, Republic of
    Withdrawn

    Not enrolling at this site — choose another above.

  • Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny
    Brzozow, 36-200, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Szpitale Pomorskie Sp. z o.o. Oddział Onkologii i Radioterapii
    Gdynia, 81-519, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o. Oddział Onkologii Klinicznej z Pododdziałem Dziennym
    Krakow, 31-826, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Clinical Research Center Sp. z o.o., Medic-R Sp. K.
    Poznan, 60-848, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • H.G.U. de Elche
    Elche, 03203, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Completed

    Not enrolling at this site — choose another above.

  • H.U. Virgen de la Victoria
    Málaga, 29010, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2018 (actual). Primary completion is estimated for Dec 2026, 101 months after the start.

Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's planned 101 months is above that.

Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2018
First posted
Jul 19, 2018
StartActual
Jul 17, 2018
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jun 30, 2028
Last update
Apr 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03592472
Lead sponsor
Xynomic Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jul 19, 2018
Start date
Jul 17, 2018
Primary completion
Dec 30, 2026 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Apr 13, 2025

Study contacts

Sophia Paspal, Ph.D.
Contact
sophia.paspal@xynomicpharma.com
6104055974
Rahul Aggarwal, M.D.
Contact
rahul.aggarwal@ucsf.edu
Pamela Munster, M.D.
study chair · University of California, San Francisco
Rahul Aggarwal, M.D.
study chair · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abexinostat

Start the discussion